Sodium zirconium cyclosilicate
目录号 : GC69923Sodium zirconium cyclosilicate 是一种口服、不吸收的新型无机微孔硅酸盐锆化合物，是一种高选择性阳离子交换剂，可选择性去除体内过量的 K+。Sodium zirconium cyclosilicate 可用于慢性肾脏疾病 (CKD) 的研究。
Cas No.:17141-74-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K+ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD)[1][2].
Sodium zirconium cyclosilicate (ZS-9) is an inorganic cation exchange crystalline compound that has a high capacity to selectively entrap monovalent cations, specifically excess K+ and ammonium ions. Sodium zirconium cyclosilicate has the exchange capacities for the divalent ions Ca2+ and Mg2+ are below 0.05 mEq/g, and a >25-fold selectivity for K+ over either Ca2+ or Mg2+[1].
Sodium zirconium cyclosilicate (ZS-9; 2-6 g/kg; p.o.; daily, for 5 d) is a recovery in feces of Sprague-Dawley rats and can efficient uptake and removal of potassium ions[2].
| Animal Model: | Sprague-Dawley rats[2] |
| Dosage: | 2, 4, and 6 g/kg |
| Administration: | Oral administration; daily, for 5 days |
| Result: | Had 99% fecal recovery in rats. Uptake and removal of potassium ions in a dose-dependent manner. |
[1]. Stavros F, et, al. Characterization of structure and function of ZS-9, a K+ selective ion trap. PLoS One. 2014 Dec 22;9(12):e114686.
[2]. Ash SR, et, al. A phase 2 study on the treatment of perkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient. Kidney Int. 2015 Aug;88(2):404-11.
| Cas No. | 17141-74-1 | SDF | Download SDF |
| 分子式 | H6O9Si3.2Na.Zr | 分子量 | 371.5 |
| 溶解度 | 储存条件 | 4°C, away from moisture | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6918 mL | 13.459 mL | 26.9179 mL |
| 5 mM | 0.5384 mL | 2.6918 mL | 5.3836 mL |
| 10 mM | 0.2692 mL | 1.3459 mL | 2.6918 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。